Application of low molecular weight heparin on immunoglobulin (IG) A,IgG , IgM, prothrombin time (PT), thrombin time (TT), fibrinogen (FIB), and activated partial thrombokinase time (APTT) , tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleuk
biomarkers in hyperlipidemic acute pancreatitis
Sažetak
Objective: To explore the impact of low molecular weight heparin (LMWH) on serum immunoglobulin (IG) A,IgG , IgM, prothrombin time (PT), thrombin time (TT), fibrinogen (FIB), and activated partial thrombokinase time (APTT) , tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8) in hyperlipidemic acute pancreatitis (HLAP) patients.
Methods: One hundred HLAP patients treated in our hospital from January 2022 to December 2024 were divided into control group (CG) and experimental group (EG). The CG accepted conventional therapy and routine nursing. Based on the conventional therapy and routine nursing, the EG accepted LMWH therapy and early enteral nutrition nursing. The recovery status and changes of various indicators were compared in 2 groups.
Results: Relative to CG, EG had higher total effective rate, shorter disappearance time of abdominal distension and abdominal pain, exhaust recovery time, defecation recovery time, bowel sound recovery time and length of hospitalization, lower serum amylase and urine amylase levels, better improvements of blood lipid markers, better improvements of coagulation function indexes, lower levels of inflammatory markers, higher levels of nutritional indexes, higher levels of immune indexes and lower incidence of complications.
Conclusion: LMWH combined with early enteral nutrition nursing is effective in the management of HLAP patients, which can promote physical recovery of patients, improve coagulation function and inflammatory response, promote nutritional status and immune function, and reduce the incidence of complications.
Sva prava zadržana (c) 2025 Yujie Lu, Xinchao Zhu, Caixia Wen, Qiang Zhang, Li Zhao, Jia Ling

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
